Standout Papers

A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase 1994 2026 2004 2015 677
  1. A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase (1994)
    David W. Fry, Alan J. Kraker et al. Science
  2. PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib (2007)
    Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Cancer Research

Immediate Impact

8 by Nobel laureates 19 from Science/Nature 84 standout
Sub-graph 1 of 16

Citing Papers

SuFEx-enabled, agnostic discovery of covalent inhibitors of human neutrophil elastase
2019 StandoutNobel
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
2018 Standout
9 intermediate papers

Works of James M. Nelson being referenced

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
2007 Standout
Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
1998

Author Peers

Author Last Decade Papers Cites
James M. Nelson 1900 646 1342 1371 57 4.3k
Fuwu Zhang 1309 241 536 2002 93 6.6k
Nial Wheate 3499 420 3026 1859 96 7.1k
Shanta Dhar 1478 606 2420 3073 101 7.7k
Timothy C. Johnstone 2827 904 2560 1539 80 5.8k
Róbert Langer 1835 1585 333 1379 99 6.7k
Kogularamanan Suntharalingam 2527 730 3424 2274 87 5.9k
Holger Stephan 1128 908 505 1386 168 5.5k
Cai‐Ping Tan 2234 502 2762 2672 104 6.7k
Wee Han Ang 3761 867 3886 1965 133 7.5k
Masaaki Abe 690 678 1044 1402 253 6.1k

All Works

Loading papers...

Rankless by CCL
2026